Tradestie Institutional Equity Comparison Engine

CGEM vs FDMT โ€” Head-to-Head Terminal

6-dimension institutional benchmarking across valuation, multi-year operating margins, normalized momentum, and dealer gamma corridors.

Market Close: 2026-11-16 Buy Verdict Report Ask Alpha

Pillar 1 Executive Scorecard & Category Winner Tally

CGEM Overall Edge

CGEM Captures Institutional Edge (3โ€“1 Pillars ยท 5โ€“5 Matrix Metrics)

Tradestie Institutional Equity Comparison Engine assigns the overall head-to-head edge to Cullinan Therapeutics, Inc. Common Stock (CGEM) driven by superior Valuation, Growth & Margin, Options & Structure while FDMT counters with relative strength in Momentum & Technical. Fundamentally, CGEM trades at 6.7x Forward P/E with 0.0% operating margin (+0.0% YoY revenue) versus FDMT at N/M Forward P/E and -222.7% operating margin (+4505.6% YoY). In options structure, CGEM sits in UNCLASSIFIED (9th %ile IV; Dealer Gamma Walls on Pro) against FDMT sits in BREAKDOWN (10th %ile IV; Dealer Gamma Walls on Pro).

Valuation Winner CGEM
CGEM 6.7x vs FDMT N/M Fwd P/E
Growth & Margin Winner CGEM
Op Margin 0.0% vs -222.7% ยท YoY +0.0% vs +4505.6%
Momentum & Technical Winner FDMT
1Y +17.5% vs +13.3% ยท 52W Pos 12% vs 47%
Options & Structure Winner CGEM
UNCLASSIFIED (9th %ile IV) vs BREAKDOWN (10th %ile IV)
CGEM NASDAQ
Cullinan Therapeutics, Inc. Common Stock
Biological Products, (No Disgnostic Substances)
$9.72
-5.45% 1D
Market Cap $653.8M
1M Return -24.83%
1Y Return +17.53%
Forward P/E 6.7x
Unified AI Score
41.0 / 100 SELL
Tech 25.0 Fund 51.0 Flow 50.0 Mom 59.0
FDMT NASDAQ
4D Molecular Therapeutics, Inc. Common Stock
Biological Products, (No Disgnostic Substances)
$11.65
-4.74% 1D
Market Cap $669.3M
1M Return -4.04%
1Y Return +13.33%
Forward P/E N/M
Unified AI Score
51.3 / 100 HOLD
Tech 51.0 Fund 47.0 Flow 66.0 Mom 54.0

Pillar 2 Normalized Relative Return Performance (% Indexed to 0%)

1Y Indexed Return: CGEM +17.53% FDMT +13.33% Spread: +4.2 pp (CGEM Lead)

Pillar 3 Operating Profitability Benchmark (Trailing 12-Month)

Split-Invariant Revenue ($B) & Operating Margin (%)
CGEM TTM Op. Margin: 0.0% FDMT TTM Op. Margin: -222.7%
Standardized multi-year USD domestic revenue schedules are unavailable for foreign-domiciled ADR filing schedules on CGEM vs FDMT. Trailing 12-month operating profitability (CGEM 0.0% vs FDMT -222.7%) and valuation multiples (CGEM 6.7x vs FDMT N/M Forward P/E) are benchmarked directly in Pillar 4 below.

Pillar 4 Head-to-Head Fundamental & Valuation Matrix

Matrix Tally: CGEM (5) vs FDMT (5)
Institutional Metric CGEM FDMT Criterion Row Winner
Market Capitalization Scale $653.8M $669.3M Larger Scale FDMT
Trailing P/E Ratio Valuation 6.7x N/M Lower Multiple CGEM
Forward P/E Ratio Valuation 6.7x N/M Lower Multiple CGEM
Revenue Growth (YoY) Growth +0.0% +4505.6% Higher Growth FDMT
Operating Margin (TTM) Profitability 0.0% -222.7% Higher Margin CGEM
Net Profit Margin Profitability 0.0% -208.6% Higher Margin CGEM
Return on Equity (ROE) Capital Efficiency -50.3% -56.7% Higher ROE CGEM
52-Week Range Position Momentum 12% ($8โ€“$23) 47% ($7โ€“$17) Stronger Trend FDMT
Beta / 30D Volatility Risk Regime 1.56ฮฒ ยท 104% Vol 1.89ฮฒ ยท 90% Vol Lower Realized Risk FDMT
Unified Institutional Score Composite Signal 41.0 / 100 (SELL) 51.3 / 100 (HOLD) Higher Composite FDMT

Pillar 5 Options Structure, IV Regime & Dealer Gamma Corridor

Full CGEM vs FDMT Buy Guide
CGEM UNCLASSIFIED
0d in phase ยท OBV NEUTRAL
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
IV Percentile 9th %ile
IV Regime Compressed (<25th %ile)
Live CGEM Put/Call Gamma Walls & dealer positioning signals require Pro. Unlock 14-Day Free Trial →
FDMT BREAKDOWN
62d in phase ยท OBV NEUTRAL
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
IV Percentile 10th %ile
IV Regime Compressed (<25th %ile)
Live FDMT Put/Call Gamma Walls & dealer positioning signals require Pro. Unlock 14-Day Free Trial →

Pillar 6 90-Day Technical & R&D Innovation Disclosures

Corporate R&D & Foundry Tracker
Neither CGEM nor FDMT registered frontier semiconductor/AI engineering publications in the trailing 90-day window; head-to-head edge is anchored on operating margin trajectory, valuation multiples, and options structure above.